Loading
institutionsInstitution
Institut Jules Bordet
Belgium's only hospital devoted entirely to cancer, birthplace of the Breast International Group and a world centre for breast cancer trials.
Also called: Jules Bordet InstituteBordetHôpital Universitaire de Bruxelles
Overview
The Institut Jules Bordet opened in 1939, named after the Nobel laureate immunologist Jules Bordet, and moved to a new building beside Erasme Hospital in Anderlecht in 2021 as part of the Hôpital Universitaire de Bruxelles. It is OECI-accredited as a comprehensive cancer centre. Martine Piccart co-founded the Breast International Group here and led the HERA trial of adjuvant trastuzumab; Christos Sotiriou's laboratory developed gene expression signatures for breast cancer and Michail Ignatiadis leads circulating tumour DNA studies, while Ahmad Awada's early-phase unit tests new agents. Bordet is also strong in haematology, nuclear medicine and surgical oncology, and Brussels hosts both BIG and EORTC headquarters.
Location
Brussels, BE
Type
cancer center · Université libre de Bruxelles
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#104 · 38 points (0 Newsweek + 0 NCI + 38 from 19 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Institut Jules Bordet, including child institutions. 489 works · 8,689 citations · 73% open access · 16% clinical trials · 2% reviews.
Oncology works per year
992022
1192023
992024
1172025
552026
Most works
- Evandro de Azambuja64 works
- Martine Piccart49 works
- Elisa Agostinetto42 works
- Matteo Lambertini35 works
- Christos Sotiriou34 works
- Mariano Suppa31 works
- Guilherme Nader Marta29 works
- Christine Desmedt28 works
- Kevin Punie26 works
- Denis Larsimont26 works
Most cited
- Breast International Group
- Breast cancer genomics and ctDNA
- Early-phase trials
- Haematology
- Nuclear medicine
Renaud Witmeur
Directeur Général of the Hôpital Universitaire de Bruxelles (H.U.B), which includes Institut Jules Bordet
Hospital managementHealth system governance
Chief executive of the Brussels University Hospital group that runs Institut Jules Bordet, Belgium's dedicated cancer institute.
Sacha Gougnard
Representative of Institut Jules Bordet to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Sacha Gougnard represents Institut Jules Bordet in the Organisation of European Cancer Institutes, which lists the centre among its members in Belgium.
Martine Piccart
Scientific Director, Institut Jules Bordet; Co-founder, Breast International Group
Breast cancerAdjuvant trastuzumabInternational trial networks
Co-founded the Breast International Group and led HERA, the trial that made adjuvant trastuzumab standard.
Evandro de Azambuja
Head of Medical Support Team, Institut Jules Bordet; Medical Oncologist
Breast cancerCardio-oncologyAdjuvant HER2 therapy
Evandro de Azambuja is a breast oncologist who studies heart safety of HER2-targeted therapy in BIG trials.
translationalJNCI: Journal of the National Cancer Institute 2020175 citations
Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach
It links the Lehmann subtypes to the spatial immune classes of Gruosso and gives a rationale for pairing checkpoint inhibitors with the immunomodulatory subtype and stromal or metabolic agents with the cold ones.
translationalGastroenterology 2018427 citations
Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features
It made subtyping possible on the archived tissue every hospital has, and it retired one of the four Bailey subtypes.
translationalAnnals of Oncology 2018323 citations
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
This is the sourced bridge between expression subtype and mutation: it tells a clinician that a LAR tumour is the one to sequence for PIK3CA and AKT1, and that immunomodulatory biology is a favourable prognostic group before any immunotherapy.
Similar pages
- CompanyBreast Cancer Trials
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), Trastuzumab, HER2-positive breast cancer.
- CompanySOLTI Cancer Research Group
Shares Breast International Group (BIG), RNA sequencing & expression profiling, Trastuzumab, HER2-positive breast cancer.
- InstitutionComprehensive Cancer Center Vienna, Medical University of Vienna / AKH
Shares Breast International Group (BIG), EORTC, Endocrine therapy (SERMs, AIs, SERDs), Diffuse large B-cell lymphoma.
- PersonPhilippe Leroy
Shares King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Organisation of European Cancer Institutes.
- CompanyGEICAM Spanish Breast Cancer Group
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- Key paperOlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer
Shares Evandro de Azambuja, Martine Piccart, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- InstitutionBrussels Cancer Centre (UZ Brussel)
Shares King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Organisation of European Cancer Institutes.
- InstitutionIstituto Oncologico Veneto IRCCS
Shares Trastuzumab, Organisation of European Cancer Institutes, HER2-positive breast cancer, Monoclonal antibodies.
cancers
fronts
technologies
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
companies
institutions
terms
people
key papers
Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment featuresUnraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approachUnravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis